William Blair analyst Matt Larew has maintained their bullish stance on RGEN stock, giving a Buy rating today.
Matt Larew has given his Buy rating due to a combination of factors that highlight Repligen’s strong market position and growth potential. Repligen’s recent financial performance showed results that were generally in line with or slightly ahead of expectations, with organic growth and financial metrics meeting consensus estimates. The company’s guidance for 2025 indicates a robust outlook, with projected revenue growth and an adjusted EBITDA margin that suggest continued strength in its market segment.
Furthermore, Repligen has shown strong momentum in its business segments, notably in CDMO and equipment orders, which have seen significant sequential and year-over-year growth. This performance supports the company’s ability to grow above the market rate, as evidenced by its guidance for non-COVID growth exceeding that of its peers. This, along with the company’s strategic positioning and recovery in the bioprocessing sector, underpins Larew’s confidence in Repligen’s potential to deliver strong shareholder returns.
In another report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $170.00 price target.